GlassScriptPhysician profile
Sunil J Desai
NPI 1588652267
$13,385.89
in general payments reported to CMS, 2019-2025
42 companies · $819 in 2025
The $819 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,408 · 2020: $1,600 · 2021: $2,258 · 2022: $2,122 · 2023: $2,115 · 2024: $2,064 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,997.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,613.20 | 2019-2025 | Farxiga, Brilinta, Wainua |
| E.R. Squibb & Sons, L.L.C. | $1,499.33 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $1,348.82 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $1,145.56 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,033.34 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $958.50 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $952.39 | 2020-2025 | Nexletol, Nexlizet |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $946.19 | 2019-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $889.46 | 2019-2024 | |
| Novo Nordisk INC | $461.95 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amarin Pharma, INC. | $298.50 | 2019-2022 | |
| Abbott Laboratories | $268.62 | 2019-2025 | Amplatzer Amulet, Cardiomems |
| Merck Sharp & Dohme LLC | $225.51 | 2021-2024 | Verquvo |
| Alnylam Pharmaceuticals INC. | $202.70 | 2022-2025 | Amvuttra, Onpattro |
| Edwards Lifesciences Corporation | $182.87 | 2019-2024 | Mitris Resilia Mitral Valve, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.